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Abstract
Marfan syndrome (MFS) is a connective tissue disorder in which aortic rupture is the major cause of death.
MFS patients with an aortic diameter below the advised limit for prophylactic surgery (<5 cm) may unexpectedly
experience an aortic dissection or rupture, despite yearly monitoring. Hence, there is a clear need for improved
prognostic markers to predict such aortic events. We hypothesize that elastin fragments play a causal role
in aortic calcification in MFS, and that microcalcification serves as a marker for aortic disease severity. To
address this hypothesis, we analysed MFS patient and mouse aortas. MFS patient aortic tissue showed enhanced
microcalcification in areas with extensive elastic lamina fragmentation in the media. A causal relationship
between medial injury and microcalcification was revealed by studies in vascular smooth muscle cells (SMCs);
elastin peptides were shown to increase the activity of the calcification marker alkaline phosphatase (ALP) and
reduce the expression of the calcification inhibitor matrix GLA protein in human SMCs. In murine Fbn1C1039G/+
MFS aortic SMCs, Alpl mRNA and activity were upregulated as compared with wild-type SMCs. The elastin
peptide-induced ALP activity was prevented by incubation with lactose or a neuraminidase inhibitor, which
inhibit the elastin receptor complex, and a mitogen-activated protein kinase kinase-1/2 inhibitor, indicating
downstream involvement of extracellular signal-regulated kinase-1/2 (ERK1/2) phosphorylation. Histological
analyses in MFS mice revealed macrocalcification in the aortic root, whereas the ascending aorta contained
microcalcification, as identified with the near-infrared fluorescent bisphosphonate probe OsteoSense-800.
Significantly, microcalcification correlated strongly with aortic diameter, distensibility, elastin breaks, and
phosphorylated ERK1/2. In conclusion, microcalcification co-localizes with aortic elastin degradation in MFS aortas
of humans and mice, where elastin-derived peptides induce a calcification process in SMCs via the elastin receptor
complex and ERK1/2 activation. We propose microcalcification as a novel imaging marker to monitor local elastin
degradation and thus predict aortic events in MFS patients.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Marfan syndrome (MFS) is a connective tissue disor-
der caused by a mutation in the fibrillin-1 gene (FBN1)
[1]. This protein is a component of microfibrils in the
extracellular matrix, and is essential for elastic fibre
integrity [2]. Fibrillin-1 protein deficiency or mutation
leads to elastin fragmentation in the aorta, contributing
to the life-threatening feature of aortic aneurysm for-
mation and dissection, as experienced by MFS patients.
Aorta pathologymostly occurs in the aortic root and tho-
racic aorta [3,4]. To prevent aortic growth and dissection,
MFS patients are treated with blood pressure-lowering
drugs and by prophylactic aortic (root) replacement [5].
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The timing of surgery is based on several risk factors,
including aortic diameter, the site of dilatation, the aortic
dilatation rate, previous aortic dissection, familial his-
tory of dissection and sudden death, and the wish to
become pregnant, owing to an enhanced risk of rupture
during pregnancy [6–11]. Dissection of the aorta, how-
ever, also occurs in patients with relatively small aorta
diameters, i.e.<5 cm,without any of the aforementioned
risk factors [12]. Therefore, novel prognostic markers
are essential to reduce this risk.
Elastic lamina degradation is a hallmark of the
diseased MFS aorta, and can be visualized in tis-
sue sections. Notably, elastin fragmentation leads
to the release of so-called elastin-derived peptides
and fibrillin-1 fragments, containing the hydrophobic
GxxPG amino acid sequence, which can bind to the
elastin-binding protein (EBP) of the elastin receptor
complex (ERC) [13,14]. Signalling via this receptor
leads to cellular processes such as proliferation and
chemotaxis, but also calcification [15–17]. There is
a complex interplay between elastic fibre breaks and
calcification, with possibly a vicious cycle whereby
elastin breaks lead to calcification, which in turn
promotes further fragmentation of the elastic fibres
[16,17–23].
Vascular calcification is associated with an increased
risk of cardiovascular death [24,25] and has been inves-
tigated in many diseases, such as chronic kidney disease,
abdominal aortic aneurysms (AAAs), and atherosclero-
sis [26–29]. In atherosclerosis research, vascular calci-
fication is often categorized into macrocalcification and
microcalcification, depending on the size of the calci-
fied lesions [30]. Whereas macrocalcification in arterial
tissues is associated with a more stable atherosclerotic
plaque phenotype [31], microcalcification is associated
with disease progression and plaque rupture [32–36].
Macrocalcification can be easily observed in vascular
sections after haematoxylin and eosin (H&E) staining,
whereas the identification of microcalcification requires
specific staining methods.
There is a clear lack of knowledge on the possible
role of macrocalcification ormicrocalcification in hered-
itary aortopathies such as MFS, and their contribution
to aortic distensibility and aortic dilatation. In chronic
kidney disease and AAA formation, elastin fragmenta-
tion promotes vascular calcification [16,17]. Recently,
elastin-derived peptides were shown to promote AAA
formation [37]. Vascular calcification has also been
visualized in thoracic aortic aneurysms, specifically in
the fibulin-4 hypomorphic and mgR MFS mouse mod-
els [38,39]. In mgR MFS mice, elastin peptides gen-
erated by elastin breaks were shown to contribute to
aortic macrophage infiltration, matrix metalloproteinase
(MMP) expression, and upregulation of transforming
growth factor (TGF)-β signalling [40]; however, their
relationship with aortic calcification was not investi-
gated. We hypothesize that elastin fragments play a
causal role in aortic calcification inMFS, and that micro-




For histochemical staining, tissue from MFS patients
was collected during prophylactic aortic surgery in
our institute, to replace the aortic root and ascend-
ing aorta. The aortic root and ascending aorta
of 2-month-old, 4-month-old and 8-month old
Fbn1C1039G/+ MFS and wild-type (WT) mice were
used for histochemical staining. The tissues were
fixed with 4% neutral buffered formaldehyde (Shan-
don Formal-Fixx; Thermo Scientific, Rockford, IL,
USA), paraffin-embedded, sectioned (7 μm), deparaf-
finized in xylene, and rehydrated. Consecutive sections
were stained with Alizarin red (Sigma, St. Louis,
MO, USA) for calcium deposits, Lawson (Klinipath,
Breda, Netherlands) to visualize elastic fibres, Mayer’s
haematoxylin (Sigma) and eosin (Merck Chemicals,
Amsterdam, Netherlands) to stain cellular nuclei/
cytoplasm and macrocalcification, and Alcian blue
(Sigma-Aldrich, St. Louis, MO, USA) for detection of
glucosaminoglycans (GAGs). The aortic root diameter
of the mice was measured as described previously [41].
In brief, the first section of the aortic root, where the
valve leaflets were no longer present, was used to mea-
sure the aortic root diameter. The luminal diameter was
calculated from images of the luminal circumference
(usingAdobe PhotoshopCS5).Macrocalcification in the
aortic valve area was measured at ×100 magnification.
Cryosections from the aortic root and the ascending
aorta of OsteoSense-800-injected mice were stained
with H&E (macrocalcification) or Lawson (elastic lam-
inae/breaks). The number of elastin breaks was counted
by a researcher blinded to the genotype (two sections per
mouse). For detection of phosphorylated extracellular
signal-regulated kinase-1/2 (pERK1/2), immuno-
histochemistry was performed on ascending aorta
cryosections. First, antigen retrieval was performed
(sodium citrate buffer, pH 6), followed by endogenous
peroxidase quenching (2%H2O2), and non-specific anti-
gen blocking with superblock (ScyTek) was performed
prior to overnight incubation with rabbit polyclonal
anti-pERK1/2 antibody (1:200, #9101; Cell Signal-
ing Technology, Leiden, Netherlands). The sections
were then incubated with a horseradish peroxidase-
conjugated polymer anti-rabbit IgG, and subsequently
developed with 3,3′-diaminobenzidine tetrahydrochlo-
ride and photographed/quantified with QWin software
(Leica Microsystems, Cambridge, UK) as the positive
area/total medial area ratio.
Smooth muscle cell (SMC) culture
Primary human umbilical artery SMCs were isolated
[42] and cultured in Dulbecco’s modified Eagle’s
medium F-12 with L-glutamine, 100U/ml penicillin,
100 μg/ml streptomycin, and 10% fetal bovine serum
(FBS). Murine aortic SMCs were isolated from
5-week-old Fbn1C1039G/+ and WT aortas [43], and
cultured with 20% FBS. Cell experiments were initiated
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at 80% confluency. SMCs were incubated for 6 or
12 days with 100 μg/ml elastin peptide VGVAPG,
scrambled peptide VVGPGA (Genecust, Ellange, Lux-
embourg), or vehicle. WT aortic SMCs were also treated
with a combination of elastin peptides and 5mM lactose,
which causes shedding of EBP to block ERC signalling
[13], or with elastin peptides and 25 μM PD98059
[mitogen-activated protein kinase kinase 1/2 (MEK1/2)
inhibitor (MEKi); Sigma] to inhibit MEK1/2. Addition-
ally, cells were treated with 300 μg/ml κ-elastin (Elastin
Products Company, Owensville, Missouri USA), i.e.
elastin fragments purified from bovine ligament that
contain the VGVAPG sequence.
Simultaneous treatment with κ-elastin and lac-
tose or with κ-elastin and 400 μM neuraminidase
inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid
(ddNeu5ac) was also performed to block ERC sig-
nalling. Finally, WT and MFS SMCs were separately
treated with 5mM lactose or 40–80 μM PD98059.
RNA isolation and reverse transcription quantitative
polymerase chain reaction (RT-qPCR)
RNAwas isolated (AurumTotal RNAMini Kit; BioRad,
Veenendaal, Netherlands), and cDNA synthesis was per-
formed (iScript cDNA synthesis kit; BioRad). Specific
primers were designed (software: Primer3) to analyse
the gene expression of different calcification markers
(supplementarymaterial, Table S1). The 60S acidic ribo-
somal protein P0 gene (RPLP0) was used as the refer-
ence gene (supplementary material, Table S1). Quan-
titative polymerase chain reaction was performed on a
Lightcycler 480 system (Sensifast no ROX SYBR green
mix; Bioline, London, UK).
Protein isolation and western blot analysis
Murine aortic tissue was lysed with RIPA buffer con-
taining 150mM NaCl, 50mM Tris–HCl, 1% Igepal-39,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
phate (SDS), and phosphatase and protease inhibitor.
The supernatant was collected after 10min of centrifu-
gation (8000× g). The protein concentration was mea-
sured (BioRad DC assay), an equal amount of protein
was loaded onto a 10% SDS polyacrylamide gel elec-
trophoresis gel, and protein transfer was performed on
a polyvinylidene difluoride membrane. pERK1/2 was
detected with a mouse monoclonal IgG2a (sc-7383;
Santa Cruz, Dallas, TX, USA), and total extracellu-
lar signal-regulated kinase-1/2 (ERK1/2) was detected
with a rabbit polyclonal IgG (#9102; Cell Signaling
Technology). α-Tubulin was used as the loading control
(CLX135AP; Cedarlane, Burlington, Canada). All anti-
bodies were diluted 1:1000. Finally, the blots were incu-
bated with the corresponding secondary IRdye-labelled
antibody (LI-COR, Lincoln, NB, USA) and visualized
with the Odyssey Infrared Imaging System (LI-COR).
Alkaline phosphatase (ALP) activity
For detection of in vitro ALP activity, cells were lysed
with cold RIPA buffer containing protease inhibitors.
Lysates were incubated overnight at 4 ∘C, and diluted 1:1
with Vector blue ALP substrate (Vector, Peterborough,
UK) in 400mM Tris–HCl (pH 8). Finally, the optical
density was measured with an EL-808 ultra-microplate
reader at a wavelength of 650 nm. ALP activity was
corrected for the protein concentration of the lysate.
Animal experiments
Animal care and experimental procedures were
approved by the independent animal experimental
committee for Animal Welfare of the Academic Med-
ical Centre and the Erasmus Medical Centre according
to the local guidelines and Directive 2010/63/EU of
the European Parliament. To study vascular macrocal-
cification, 2-month-old, 4-month-old and 8-month-old
Fbn1C1039G/+ mice (MFS; n= 114) and WT mice
(n= 38) were analysed. The mice are maintained on
a C57Bl6/J background as a heterozygous breed-
ing colony in our mouse facility. Eight-month-old
Fbn1C1039G/+ male and female mice (n= 11) were
used for the in vivo near-infrared fluorescence (NIRF)
study with OsteoSense-800 and MMPSense-680
(PerkinElmer, Boston, MA, USA). Eight-month-old
WT littermates (n= 7) were included as a reference
group. The mice were injected twice (1 and 3 days
prior to imaging; intraperitoneal injections) with the
fluorescent bisphosphonate OsteoSense-800 probe, and
once (1 day prior to imaging; intravenous injection) with
the MMPSense-680 probe (2 nmol/25 g body weight).
In vivo imaging was performed under isoflurane anaes-
thesia (4% isoflurane for induction; 3% isoflurane
for maintenance). NIRF imaging was performed with
a fluorescence tomography device (FMT, 2500XL;
PerkinElmer). Transthoracic echocardiography was
performed on a subset of mice at the Erasmus Medical
Centre with a Vevo2100 high-resolution imaging system
and a 32–56-MHz probe to measure the aortic (root and
ascending) diameter and distensibility (RMV704 scan-
head; VisualSonics, Toronto, Canada). The remaining
mice underwent ultrasound investigation at the Aca-
demic Medical Centre, with a Vevo770 high-resolution
imaging system and a 40-MHz probe (RMV704 scan-
head; VisualSonics). The distensibility was calculated
by subtracting the measured ascending aortic diameter
in diastole from the systolic aortic diameter, and then
dividing it by the diastolic aortic diameter (WT, n= 4;
MFS, n= 9). After the mice had been killed, the heart
and aorta were perfused with saline, fixed, and imaged
on the Odyssey Infrared Imaging System. Intensity was
assessed with ImageJ.
Statistical analysis
Statistical tests were performed with GraphPad Prism
5 software. Graphs represent mean± standard error of
the mean. To analyse differences between two groups,
Student’s t-test or the Mann–Whitney U-test was used,
as appropriate. Proportions were analysed with Fisher’s
exact test. Association analysis was performed with
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Figure 1. Elastin breaks and microcalcification in the ascending aorta of an MFS patient. (A) Elastin in the dilated ascending aorta of an
MFS patient was visualized by Lawson staining of tissue sections. Elastin fragmentation was most pronounced in the middle of the media,
resulting in less intense staining (magnification: ×12.5). (B) The boxed area in (A) is shown at greater magnification with extensive elastin
breaks above the dotted line (magnification: ×100) [detail from (A)]. (C) Photomicrograph depicting a detail of elastic lamina damage
(magnification: ×400) [boxed area in (B)]. (D) In a consecutive section, microcalcification was visualized by Alizarin red staining. The
area of microcalcification co-localized in the middle of the aortic media with the area of most extensive aortic wall damage, as shown
in (A) (magnification: ×12.5). (E) Calcium deposits were localized in the same area as in (B), where extensive elastin breaks are present
(magnification: ×100) [detail from (D)]. (F) Photomicrograph depicting a detail of the calcium deposits (magnification: ×400) [boxed area
in (E)].
Pearson’s correlation test. A P value of ≤0.05 was
considered to be statistically significant.
Results
Microcalcification co-localizes with elastic lamina
fragmentation in MFS
To study the co-localization between the loss of elastin
fibre integrity and vascular calcification in the human
MFS aorta, sections of the ascending aorta of an MFS
patient were stained for elastin (Lawson) and calcium
deposits (Alizarin red). In this aortic section, areas of
extensive elastin fragmentation showed reduced Law-
son staining primarily in the centre of the aortic media
(Figure 1A; larger magnifications in Figure 1B, C). We
observed microcalcification in the ascending aorta as
visualized by Alizarin red staining (Figure 1D–F). The
microcalcification in the centre of the aortic media co-
localized with the area of reduced elastic fibre integrity.
Elastin peptides induce SMC calcification
Elastin fragmentation, as observed in the MFS aorta,
leads to the formation of elastin peptides [44] that can
interact with ERC [13]. ERC consists of EBP, which is
a splice variant encoded by the β-galactosidase-1 gene
(GLB1) [15], cathepsin A (CTSA), and neuraminidase-1
(NEU1). ERC mediates signalling, resulting in cellular
processes such as proliferation and differentiation, as
well as increased cytokine and protease expression [15],
and calcification [21,23]. We found that GLB1, which
encodes β-galactosidase-1 and EBP, is expressed in
human arterial SMCs (supplementary material, Figure
S1A), and that the specific mRNA transcript variant
encoding EBP (GLB1 variant 2) is also present (supple-
mentary material, Figure S1B). In addition, CTSA and
NEU1 are expressed (supplementary material, Figure
S1C, D). To study the effect of elastin peptides on
vascular calcification in detail, SMCs were treated with
the elastin peptide VGVAPG containing the GxxPG
consensus sequence, which is repeated frequently in
tropoelastin [45], or with the peptide VVGPGA as a
scrambled control.
In SMCs, elastin peptide treatment caused a 1.8-fold
increase in tissue-non-specific ALP (ALPL) mRNA
(Figure 2A). ALP is a protein that promotes vascular cal-
cification by decreasing the level of the mineralization
inhibitor pyrophosphate (PPi) [46,47]. There was also
a two-fold decrease in the mRNA level of matrix GLA
protein (MGP) (Figure 2B), which inhibits calcification
by antagonizing bonemorphogenetic protein (BMP) and
by binding to hydroxyapatite [48,49]. These results indi-
cate an induced calcification process.
ALP activity is induced via ERK1/2
In murine aortic SMCs, the elastin peptides induce a
two-fold increase in ALP activity (Figure 2C). To assess
Copyright © 2017 Pathological Society of Great Britain and Ireland. J Pathol 2017; 243: 294–306
Published by John Wiley & Sons, Ltd. www.pathsoc.org www.thejournalofpathology.com
298 S Wanga et al
Figure 2. Elastin peptides enhance ALP activity in MFS SMCs via ERC and ERK1/2 signalling. (A) Elastin-derived peptides upregulated ALP
liver/bone/kidney (ALPL) mRNA in human SMCs (n= 9 wells per group). (B) Matrix GLA protein (MGP) mRNA expression was downregulated
in human SMCs by the elastin peptides. (C) In WT aortic SMCs, elastin-derived peptide (E) treatment increased ALP activity (normalized for
protein content) as compared with scrambled peptides (S) (optical density units per mg/ml; n= 12). Simultaneous treatment with lactose
(L), an ERC antagonist, or MEKi, an inhibitor of the ERK1/2 pathway, attenuated the effect of elastin peptides on ALP activity (n= 6–9).
(D) Similarly, κ-elastin (kE) treatment upregulated ALP activity as compared with control (C), and this effect could be partially blocked
by lactose (L) or ddNeu5ac (N), a neuraminidase inhibitor (n= 3). (E) Alpl mRNA Arbitrary Unit (AU) expression was increased in MFS
aortic SMCs (n= 6) as compared with WT SMCs (n= 4). (F and G) Bone γ-carboxyglutamic acid-containing protein (Bglap) mRNA (F) and
runt-related transcription factor-2 (Runx2) mRNA (G) were also upregulated 5.5-fold and 1.4-fold, respectively, in MFS aortic SMCs. (H)
The basal ALP activity was increased in murine MFS (black bars) versus WT (white bars) aortic SMCs (n= 15). Treatment of MFS murine
SMCs with lactose (L) or MEKi reduced basal ALP activity dose-dependently (n= 6–9) as compared with vehicle-treated cells (V). *P < 0.05,
**P ≤ 0.01, ***P < 0.001.
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whether the enhanced ALP activity was mediated via
activation of ERC, we applied lactose, which is a known
antagonist of ERC by shedding of EBP [13]. The elastin
peptide-induced ALP activity was indeed attenuated
by lactose treatment (Figure 2C). Similarly, this was
observed when more natural elastin fragments were
used, so-called κ-elastin, purified from bovine ligament
(Figure 2D). In addition, more specific inhibition of
ERC was shown when ddNEU5ac was used to block
NEU1; this suppressed the upregulation of ALP activity,
accentuating the involvement of ERC in the calcifica-
tion process (Figure 2D). To further investigate which
signalling pathway is involved, SMCs were treated with
a MEK1/2 inhibitor (MEKi), to prevent ERK1/2 phos-
phorylation. MEKi blocked the increase in ALP activity
(Figure 2C), indicating that the ERK1/2 pathway is
involved in elastin peptide-mediated signalling.
ERC and ERK1/2 signalling contribute
to MFS-related SMC calcification
The role of ALP in MFS-related calcification was
investigated by comparing WT and MFS aortic SMCs.
The Glb1, Ctsa and Neu1 genes, encoding compo-
nents of ERC, are expressed in murine aortic WT and
MFS SMCs, and Glb1 expression and Ctsa expression
are enhanced in MFS SMCs (supplementary material,
Figure S1E–G). Interestingly, MFS SMCs showed an
enhanced osteogenic profile by an increase in basal
mRNA levels of the genes Alpl, bone γ-carboxyglutamic
acid-containing protein (Bglap), and runt-related tran-
scription factor-2 (Runx2) (increased two-fold, 5.5-fold
and 1.4-fold, respectively) (Figure 2E–G). In line with
these data, ALP activitywas increased three-fold inMFS
SMCs (Figure 2H), whereas these cells were not stim-
ulated by elastin peptides. Lactose treatment reduced
ALP activity in the MFS SMCs (Figure 2H), suggesting
enhanced elastin-mediated signalling in MFS SMCs in
culture. Blockade of ERK1/2 signalling by MEKi also
reduced ALP activity in a dose-dependent fashion in
MFS SMCs (Figure 2H).
Here, we show that elastin peptides promote an SMC
calcification phenotype, and that SMCs derived from
MFS mice show increased basal ALP activity, which
can be blocked by inhibition of ERC and ERK1/2 sig-
nalling. These data are in line with the observation in
human MFS aorta that microcalcification co-localizes
with elastin degradation.
Macrocalcification is prominent in the murine MFS
aortic root
So far, calcification studies in MFS mice have been
limited. Upon close inspection of aortic root histology
(H&E staining), overt signs of macrocalcification were
frequently observed in MFS mice (Figure 3). GAGs are
long unbranched polysaccharides that are known to be
abundant in cartilage and bone, and to accumulate in
areas of vascular calcification [38,39,50,51]. Detection
of GAGs by Alcian blue staining revealed that, pre-
dominantly, the SMC-containing medial area becomes
calcified in MFS mice (Figure 3A). To visualize cal-
cium deposits, we applied Alizarin red, which revealed
acellular calcium deposits and deposition surrounding
osteoblast-like cells (Figure 3A).
To evaluate whether macrocalcification in the aor-
tic root is different between WT and MFS mice, we
quantified the percentage of mice with osteoblast-like
cells per age group. Vascular calcification in the aortic
root increased with age only in MFS mice, with preva-
lence rates of 10% in 2-month-old mice and 70% in
8-month-old mice (Figure 3B). This did not occur inWT
mice, with prevalence rates of 10% in in 2-month-old
mice and 11.1% and 8-month-old mice (Figure 3B).
There was a modest significant correlation between the
area of calcium deposits and/or osteoblast-like cells, and
aortic root diameter in 4-month-old mice (Figure 3C). In
conclusion, macrocalcification in the aortic root of MFS
mice is strongly enhanced, but there is only a modest
correlation with aortic dilatation.
Microcalcification is abundant in the ascending
aorta of MFS mice
To study calcification in vivo, we used the NIRF bis-
phosphonate probe OsteoSense-800, which is known
to bind to hydroxyapatite. This probe has already suc-
cessfully been used in mice with atherosclerosis to
reveal calcification in atherosclerotic plaques [52]. The
OsteoSense-800 probe was injected into 8-month-old
WT and MFS mice, for subsequent monitoring of active
incorporation in the vasculature. A positive signal was
observed in the heart area in vivo, but it was not
detailed enough for quantification (supplementary mate-
rial, Figure S2A). On closer inspection, OsteoSense-800
signal could be observed in the aortic root, and did
indeed co-localize with macrocalcification (supplemen-
tary material, Figure S2B). Upon ex vivo imaging of
the heart and entire aorta, the OsteoSense-800 probe
revealed extensive calcification (green) in the ascending
aorta ofMFSmice (Figure 4A), whereas notmuchNIRF
signal was observed in the arch and descending aorta
(Figure 4B). In comparison, the MMPSense-680 probe,
used to visualize MMP activity, was abundant through-
out the heart and ascending aorta in both WT and MFS
mice, and there was no significant difference between
the groups (supplementary material, Figure S2C, D). To
further investigate the calcified ascending aorta, sections
were studied. The OsteoSense-800 probe was visible in
the medial area at sites with extensive elastin breaks
(Figure 4C; elastin appears as red autofluorescence),
which is similar to what was observed in MFS patients
(Figure 1). Interestingly, these calcium deposits could
only be visualized by the OsteoSense-800 probe. As
there were no overt signs of large acellular calcium
deposits or osteoblast-like cells, the vascular calcifica-
tion process in the ascending aorta may be considered
to be microcalcification [53]. To assess whether aortic
microcalcification is enhanced in MFS mice, we quan-
tified the intensity of OsteoSense-800 in whole-mount
ascending aorta, and this revealed a significant increase
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Figure 3. Macrocalcification in the murine MFS aortic root. (A) Photomicrographs of aortic root sections of three MFS mice are depicted
(magnification: ×100). Consecutive sections were stained with H&E, Alcian blue, and Alizarin red. Osteoblast-like cells were observed in
the aortic medial layer (arrows, upper panels) of the MFS mice. GAGs (Alcian blue; middle panels) and calcium deposits (Alizarin red; lower
panels) surrounded these bone-like cells. Insets show osteoblast-like cells in more detail (magnification: ×400). (B) In MFS mice (n= 114),
the percentage of mice with calcification increased with age, whereas this was not observed in WT mice (n= 38). (C) There was a weak but
significant correlation between the area of calcification in the aortic root and aortic root diameter (grey dots are WT mice and black dots
are MFS mice). *P < 0.05, **P ≤ 0.01.
inmicrocalcification inMFSmice as comparedwithWT
mice (Figure 4D). In conclusion, microcalcification is
more abundant in theMFS ascending aorta in close prox-
imity to elastin fragmentation.
ERK1/2 signalling is correlated with aortic
microcalcification
As mentioned above, ERK1/2 inhibition resulted in
a decrease in ALP activity after elastin peptide stim-
ulation and in murine MFS SMCs. Here, we show
that pERK1/2 was significantly increased in the MFS
ascending aorta as compared with WT ascending
aorta lysates (Figure 5A, B). To determine where the
enhanced ERK1/2 signalling is present in the aorta and
whether there is a relationship with aortic microcalci-
fication, immunostaining for pERK1/2 was performed
on aorta sections from the OsteoSense-800-injected
mice. Enhanced pERK1/2 was observed in SMCs in
the aortic media, and correlated significantly with
the OsteoSense-800 signal (Figure 5C, D; r= 0.62,
P= 0.02).
Aortic dilatation, distensibility and elastin breaks
are correlated with aortic microcalcification
As previous studies have shown that ERK1/2 signalling
plays a pivotal role in the progression of MFS aortic
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Figure 4. Microcalcification in the MFS mouse ascending aorta. (A) OsteoSense-800, a bisphosphonate-conjugated fluorescent probe, was
injected intraperitoneally into WT and MFS mice. This probe binds to sites of vascular calcification (green). The aortas of WT and MFS
mice were harvested, and the OsteoSense-800 was visualized ex vivo with an Odyssey scanner. (B) Examples of one WT mouse and three
different MFS mice. The boxed area in (A) (white frame) is shown at greater magnification. The OsteoSense-800 (green) localized in the
ascending aorta (arrow), originating from the aortic root (*). There was minimal signal in the descending aorta (arrowhead). (C) A section
of the ascending aorta of an MFS mouse revealed accumulation of the OsteoSense-800 (green) in the medial layer of the vascular wall.
Cell nuclei were stained blue, and the elastic laminae showed red autofluorescence. (D) Significantly more fluorescence was incorporated
in the MFS (n= 11) than in the WT (n= 7) ascending aortas, as quantified from the whole mount scans (as fold induction relative to WT
mice). **P ≤ 0.01.
disease [54–56], it is important to describe the various
pathological features in relation to microcalcification.
Aortic dilatation of the ascending aorta, as determined
by echocardiography, correlated positively with micro-
calcification (Figure 5E; r= 0.55, P= 0.050). In MFS, a
known risk factor for aortic growth/dissection is aortic
distensibility [57], which is a marker for aortic elas-
ticity. When the distensibility decreases, it is consid-
ered that the elastic laminae are compromised and that
the aorta has therefore become more stiff [57]. Indeed,
upon quantification, the number of elastin breaks was
six-fold higher in the MFS mouse aorta where the
distensibility was the lowest (supplementary material,
Figure S3). Interestingly, in MFS mice, a strong neg-
ative correlation between calcification and distensibil-
ity was observed (Figure 5F; r= –0.71, P= 0.006).
In addition, a positive correlation between calcifica-
tion and the number of elastin breaks was observed
(Figure 5G, H; r= 0.65, P= 0.021), which is in line
with our in vitro experiments showing enhanced ALP
activity after elastin peptide treatment. On the basis
of these data, microcalcification may be considered a
marker for local aortic damage in MFS mice. In sum-
mary, we propose that elastin fragmentation in the MFS
aorta leads to increased microcalcification via activa-
tion of ERC and subsequently ERK1/2 signalling, result-
ing in enhanced ALP activity and microcalcification
(Figure 6).
Discussion
In the current study, we observed extensive microcal-
cification, not macrocalcification, in the human MFS
ascending aorta. In line with our data, aortic calci-
fication in MFS patients is not visible on a com-
puted tomography (CT) scan. On histochemical stain-
ing in the MFS aorta, microcalcification became appar-
ent and co-localized with areas of severe elastin frag-
mentation, suggesting a causative relationship. Regard-
ing this hypothesis, we demonstrated that elastin pep-
tides induced a calcification process in cultured human
and mouse arterial SMCs as revealed by enhanced ALP
and reduced MGP expression. In addition, cultured
murine MFS aortic SMCs showed enhanced Alpl, Bglap
and Runx2 mRNA expression and increased basal ALP
activity, confirming the osteogenic potential of these
SMCs. Study of macrocalcification and microcalcifica-
tion in ageing MFS mice revealed that macrocalcifica-
tion in the aortic root correlated only mildly with aortic
diameter, whereas microcalcification in the ascending
aorta was strongly associated with aortic diameter, dis-
tensibility, and elastin degradation.
Vascular calcification is controlled by balancing
extracellular calcium and phosphate levels versus the
PPi level, which are regulated by multiple proteins;
ALP is known to decrease the PPi level [46], and MGP
reduces the level of the osteogenic growth factor BMP
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Figure 5. Aortic diameter, distensibility, elastin breaks and pERK1/2 in relation to microcalcification. (A) Western blot for pERK1/2, total
ERK1/2 and α-tubulin in WT and MFS ascending aortas. (B) The pERK1/2 level (corrected for total ERK1/2) was significantly higher in the
MFS ascending aorta (n= 7) than in the WT ascending aorta (n= 5). (C) Representative photomicrographs of pERK1/2 immunostaining of
the ascending aorta of a WT mouse and an MFS mouse (magnification: ×200). A, adventitia; L, lumen. (D) pERK1/2 staining correlated
positively with the OsteoSense-800 signal. (E) The amount of OsteoSense-800 accumulation correlated with ascending aorta diameter (in
mm) (grey dots are WT mice and black dots are MFS mice). (F) There was a strong negative correlation between the OsteoSense-800 signal
and ascending aorta elasticity, also known as distensibility (%). (G) Representative photomicrographs of the elastic laminae as visualized by
Lawson staining of the ascending aorta of a WT mouse and an MFS mouse (magnification: ×200). A, adventitia; L, lumen. (H) The number
of elastin breaks in the aorta correlated positively with the OsteoSense-800 signal. *P < 0.05.
and also directly binds to hydroxyapatite [48,49]. In
our SMC cultures, we observed a disturbed balance,
with enhanced ALP and reduced MGP expression in
response to elastin peptide stimulation. MGP-deficient
mice have extensive spontaneous arterial calcification
[58], which can be reduced by BMP inhibitors [59].
Elastin haploinsufficiency can also inhibit arterial
calcification in MGP-deficient mice, independently
of BMP signalling. The latter is explained by the
function of elastin as an accelerator of calcification
[19]. In line with our data, it was demonstrated that
elastin peptides induced ALP activity in rat SMCs and
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Figure 6. Mechanism underlying MFS aortic microcalcification:
schematic overview of the main findings of this study. Elastin pep-
tides (purple strings) generated by local aortic elastin fragmen-
tation bind to ERC, which consists of EBP, CTSA, and NEU1. This
causes ERK1/2 phosphorylation via MEK1/2, which leads to an
ERK1/2-dependent increase in ALP activity. ALP causes hydrolysis
of PPi, an inhibitor of calcification, and generates phosphate (Pi).
Calcium phosphate crystals, in the form of hydroxyapatite, precip-
itate, causing microcalcification in the MFS aorta, which functions
as a marker for aortic damage and may increase the risk of aortic
rupture.
fibroblasts [21,22] and increased ERK1/2 signalling
[13,60]. Moreover, the ERK1/2 pathway is profoundly
involved in aggravating MFS aortic disease [54–56,61].
Other studies have already linked ERK1/2 signalling
to vascular calcification [62,63]. Here, we showed
that elastin peptides increased ALP activity in an
ERC-dependent and ERK1/2-dependent manner in
SMCs. Basal ALP activitywas already enhanced inMFS
aortic SMCs, and could be normalized by the ERC and
ERK1/2 inhibitor lactose, the neuraminidase inhibitor
ddNeu5ac, and MEKi. In the Fbn1C1039G/+ MFS mouse
model, we observed macrocalcification with large
calcium deposits and osteoblast-like cells in the medial
area of the aortic root, which was almost absent in
WT mice. In addition, microcalcification was revealed
in the MFS ascending aorta with the NIRF probe
OsteoSense-800. Hypomorphic mgR/mgR MFS mice
are known to have increased medial microcalcification
in the ascending aorta [38], and it would be of interest to
study whether macrocalcification is present in the aortic
root of these mice. In contrast, macrocalcification is
present in the aortic root of fibulin-4R/R mice [39], but,
in this mouse model, microcalcification in the ascending
aorta was never studied. Altogether, these data indi-
cate potential common signalling pathways between
the distinct genetic aneurysm mouse models in which
different extracellular matrix proteins are mutated. It is
of note that both fibulin-4 and fibrillin-1 are necessary
for proper elastin fibre assembly [64], and lack of either
of these proteins may impair elastin homeostasis.
The relationship between elastin fragmentation and
calcification has been observed before. Elastin fragmen-
tation precedes vascular calcification [17,18,21–23],
but calcium crystals can also cause damage to elastin
fibres [19,20]. In addition, cellular vesicles, derived
from apoptotic cells, can induce vascular calcification in
atherogenic mouse models [65], thereby causing elastin
degradation. Moreover, TGF-β increases ALP activity
and microcalcification via collagen receptor discoidin
domain receptor-1-mediated vesicle release by SMCs
[66]. As enhanced TGF-β signalling is also a hallmark of
MFS pathology, together with elastin fragmentation and
SMC death, these processes may all be relevant and act
synergistically to cause aortic calcification and further
aortic damage in MFS.
In atherosclerosis, microcalcification is associ-
ated with enhanced atherosclerotic plaque rupture
[33–36,67], and thus contributes to enhanced morbidity
and mortality. A causal role for microcalcification
during aneurysm formation has become clear from
the adapted calcium phosphate-induced AAA model,
with enhanced aneurysm growth as compared with the
original calcium chloride model [68]. Further studies
are needed to determine whether inhibition of aortic
calcification with, for example, an ALP inhibitor [47]
could serve as therapeutic option forMFS aortic disease.
In this study, we focused on aortic microcalcification
in MFS, but our findings might also apply to other aor-
topathies. Patients with bicuspid aortic valves, patients
with familial thoracic aortic aneurysm and dissection
or chronic heart failure patients with left ventricular
assist devices also show aortic elastinolysis [69–71].
The presence of aortic microcalcification and its role in
these aortopathies, however, still need to be determined.
Visualization of microcalcification in vivo in humans
is feasible with positron emission tomography andX-ray
CT imaging with [18F]sodium fluoride as tracer, which
adsorbs to calcified deposits [72]. So far, aortic cal-
cification has been underappreciated in aortopathies,
but we now demonstrate that, especially, aortic micro-
calcification at sites of elastic lamina fragmentation is
abundant and may contribute to aortic destabilization.
Our data strongly support the performance of a human
study to determine the predictive value of local aortic
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microcalcification, as determined by aortic imaging with
the [18F-]sodium fluoride tracer, as a risk factor for aor-
tic growth or, even more relevant, as an indicator of an
increased risk for aortic dissection.
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